Physician

Eric Joseph Palfreyman, M.D.

According to 2025 Medicare claims, Eric Palfreyman, M.D. (NPI: 1356504690) practices rheumatology in the Boise City, ID market, with the plurality of this provider's patient population coming from Ada, ID. This provider's primary affiliated billing organization is IDAHO ARTHRITIS & OSTEOPOROSIS CENTER PC (NPI: 1770539298; TIN: 820536242) and primary practice location at 83642-5510. Palfreyman is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Palfreyman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 508 traditional Medicare patients, billed 134,109 HCPCS/CPT codes, and received $2,232,206 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,033 prescription claims across 576 beneficiaries totaling $2,085,540 in drug costs, led by Enbrel Sureclick (Etanercept). Open Payments data shows 2 records totaling $72. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $378,262 to $2,232,206. Similarly, Part D prescription costs have risen steadily, from $785,045 to $2,085,540. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	322	32,814	$378,262
2016	377	28,018	$459,720
2017	406	22,791	$597,376
2018	481	26,618	$854,113
2019	493	51,890	$1,163,495
2020	499	67,863	$1,333,070
2021	507	65,404	$1,327,685
2022	477	86,647	$1,429,374
2023	441	97,783	$1,413,124
2024	508	134,109	$2,232,206

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	383	2,680	$785,045
2016	419	3,358	$1,342,474
2017	482	3,369	$1,506,659
2018	515	3,271	$1,353,480
2019	566	3,214	$1,335,981
2020	530	2,922	$1,442,054
2021	541	2,599	$1,319,928
2022	556	2,417	$1,426,384
2023	483	2,117	$1,444,735
2024	576	3,033	$2,085,540

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	403	778	$85
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	379	572	$12
80053	Blood test, comprehensive group of blood chemicals	371	897	$10
36415	Insertion of needle into vein for collection of blood sample	397	1,022	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	345	870	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	55	1,764	$453,366
Enbrel Mini	Etanercept	44	1,344	$336,824
Xeljanz Xr	Tofacitinib Citrate	58	1,740	$332,625
Rinvoq	Upadacitinib	33	1,110	$238,198
Humira(Cf) Pen	Adalimumab	24	672	$155,029

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$72	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eric Joseph Palfreyman, M.D.?

Tedicare shows public-source Medicare data for Eric Joseph Palfreyman, M.D. (NPI 1356504690), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eric Joseph Palfreyman, M.D. have ACO affiliation data?

Eric Joseph Palfreyman, M.D. is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Eric Joseph Palfreyman, M.D.?

Eric Joseph Palfreyman, M.D. is linked to IDAHO ARTHRITIS & OSTEOPOROSIS CENTER PC (billing NPI 1770539298) in the available physician profile data.

Does Eric Joseph Palfreyman, M.D. have Open Payments data?

Eric Joseph Palfreyman, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.